Physician profile
Victor Farah
NPI 1396825253
$97,865.83
in general payments reported to CMS, 2019-2025
31 companies · $30K in 2025
The $30K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,165 · 2020: $398 · 2021: $961 · 2022: $9,004 · 2023: $27K · 2024: $28K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Consulting Fee: $19K · Travel and Lodging: $10K · Food and Beverage: $9,488 · Education: $26.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,526.00 |
| Consulting Fee | $18,948.09 |
| Travel and Lodging | $10,348.85 |
| Food and Beverage | $9,488.44 |
| Education | $26.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $68,067.41 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $15,263.46 | 2019-2025 | Mitraclip, Coroflow, Triclip |
| United Imaging Healthcare North America, INC. | $7,800.00 | 2025 | Ultrasound |
| Amgen INC. | $1,178.41 | 2020-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,012.91 | 2021-2025 | Wainua, Farxiga |
| Janssen Pharmaceuticals, INC | $847.45 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $599.45 | 2019 | |
| Pfizer INC. | $423.37 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.50 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $252.46 | 2022-2025 | Ozempic, Wegovy |
| Alnylam Pharmaceuticals INC. | $243.03 | 2024-2025 | Onpattro, Amvuttra |
| Medtronic, INC. | $235.24 | 2024-2025 | Micra, Corevalve Evolut R |
| Cardiac Dimensions, INC. | $171.64 | 2024 | |
| Novartis Pharmaceuticals Corporation | $168.10 | 2022-2025 | |
| Jenavalve Technology, INC. | $148.09 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $138.28 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $124.78 | 2019 | |
| Esperion Therapeutics, INC. | $124.66 | 2020 | |
| Vifor Pharma, INC. | $122.04 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.53 | 2021-2025 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $82.28 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $68.84 | 2025 | Verquvo |
| Lantheus Medical Imaging, INC. | $66.90 | 2019-2022 | |
| Bracco Diagnostics INC. | $34.29 | 2021-2023 | |
| Angiodynamics, INC. | $31.46 | 2021 | |
| Heartflow, INC. | $30.15 | 2025 | |
| Edwards Lifesciences Corporation | $25.88 | 2023 | |
| Abiomed | $24.72 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $21.15 | 2025 | Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $16.35 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Farah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.